Advances in Cardiovascular Pharmacotherapy. IX. Protection Against Major Adverse Cardiovascular Events by Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Obesity
Advances in Cardiovascular Pharmacotherapy. X. Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure and Mechanisms of Protection
Building Resilience in Academic Science and Medicine
Advances in Cardiovascular Pharmacotherapy. VIII. Angiotensin II in Vasodilatory Shock
Endothelial NOX1 Drives Obesity via Skeletal Muscle Mitochondrial Dysfunction
Advances in Cardiovascular Pharmacotherapy: VII. Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension and Heart Failure
Guidelines for Evaluating Endothelial Function in Vascular Tissue
The Association Between Preoperative Tamsulosin Use and Intraoperative Hypotension
Advances in Cardiovascular Pharmacotherapy. VI. Sacubitril-Valsartan, An Angiotensin Receptor-Neprilysin Inhibitor
Why Does My Patient Have Endocarditis?
Estrogen Influences Human Microvascular Endothelial Function Via Sex-Specific Regulation of Sphingolipids
Advances in Cardiovascular Pharmacotherapy. V. Molecular Targets in Transthyretin Amyloid Cardiomyopathy
Assessment of Anesthetic Modalities in Otologic Surgery
Pecto-intercostal fascial plane block with or without rectus sheath block in cardiac surgery: a prospective, randomized, double-blind placebo-controlled study
Advances in Cardiovascular Pharmacotherapy. IV. Sodium-Glucose Cotransporter Type 2 Inhibitors, Part 2: Mechanisms for Myocardial Protection, Adverse Effects, and Perioperative Implications
Advances in Cardiovascular Pharmacotherapy. III. Sodium-Glucose Cotransporter Type 2 Inhibitors, Part 1: Efficacy in Heart Failure and Myocardial Infarction
From the operating room to the bench: use of reverse translation to identify targets in aortic aneurysm
No publications match your search.